ERBB2 and gastric cancer: The addition of monoclonal anti-CLDN18.2 antibody Zolbetuximab to chemotherapy has led to significant improvement in median OS and is now considered to be the standard-of-care option in the first-line setting for patients with CLDN18.2-positive, HER2-negative GC and GEJ tumors [43].